News
SLNO
45.87
+1.66%
0.75
Weekly Report: what happened at SLNO last week (0429-0503)?
Weekly Report · 22h ago
Soleno Therapeutics Inc <SLNO.OQ> expected to post a loss of 37 cents a share - Earnings Preview
Soleno Therapeutics Inc expected to post a loss of 37 cents a share. The average analyst rating on the shares is "strong buy" The company is expected to show change in quarterly revenue when it reports results on May 7 for the period ending March 31 2024.
Reuters · 3d ago
Soleno Therapeutics announces pricing of $138M public offering
Healthcare Soleno Therapeutics announces pricing of $138M public offering of 3 mln shares of its common stock at a public offering price of $46.00 per share. The gross proceeds of the public offering are expected to be approximately $138.0 million.
Seeking Alpha · 4d ago
Reported Earlier, Soleno Therapeutics Prices $138M Public Offering Of 3M Common Stock At $46/Share
Soleno has also granted the underwriters a 30-day option to purchase up to 450,000 shares of common stock. The public offering is expected to close on or about May 7, 2024. The company is based in New York City and is valued at $1.5 billion.
Benzinga · 4d ago
Soleno Therapeutics Prices Public Offering Of 3 Mln Shares At $46/shr; Stock Down In After-hours
NASDAQ · 4d ago
*Soleno to Use Proceeds to Fund R&D on Lead Product Candidate >SLNO
Dow Jones · 4d ago
*Piper Sandler, Guggenheim Securities Among Managers for Soleno Offfering >SLNO
Dow Jones · 4d ago
*Soleno Has Granted Underwriters Option to Purchase Up to 450,000 Shares >SLNO
Dow Jones · 4d ago
*Soleno Therapeutics Offering 3M Shares at $46.00 Each >SLNO
Dow Jones · 4d ago
*Soleno Offering Is Expected to Close on or About May 7 >SLNO
Dow Jones · 4d ago
SOLENO THERAPEUTICS INC - PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 3 MLN SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $46.00 PER SHARE
Reuters · 4d ago
*Soleno Therapeutics Announces Pricing of About $138M Public Offering of Common Stock
Dow Jones · 4d ago
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock
Soleno Therapeutics, Inc. Announced pricing of the underwritten public offering of 3,000,000 shares of its common stock. The gross proceeds of the public offering are expected to be approximately $138.0 million. The public offering is expected to close on or about May 7, 2024. Soleno is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases.
Barchart · 4d ago
Soleno Therapeutics Announces Proposed Public Offering Of Common Stock; No Size Or Amount Disclosed
Soleno Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. The company intends to offer and sell shares of its common stock in an underwritten public offering. Soleno intends to grant the underwriters a 30-day option to purchase an additional number of shares.
Benzinga · 4d ago
SOLENO THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK
Reuters · 4d ago
Soleno Therapeutics Announces Peer-Reviewed Publication Of Data Comparing DCCR Treatment To The Natural History Of Prader-Willi Syndrome
Soleno Therapeutics, Inc. Is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Soleno published results of a study comparing results of its DCCR treatment in patients with Prader-Willi syndrome to data from the PATH for PWS natural history study in the Journal of Neurodevelopmental Disorders.
Benzinga · 6d ago
Soleno: Mid-2024 NDA Filing For PWS Treatment Is A Major Catalyst To Watch
Soleno Therapeutics, Inc. Is gearing up to file a New Drug Application to the FDA of Diazoxide Choline for the treatment of patients with Prader-Willi Syndrome in mid-2024. The company's DCCR is expected to be approved for the $2.11 billion market for the disease in 2018. Soleno has been able to advance several studies using this drug in PWS.
Seeking Alpha · 04/29 20:02
US Stocks Kick Off The Week In The Green, Tesla Rockets On China's FSD Approval, Yen Rallies: What's Driving Markets Monday?
The S&P 500 rose 0.2% by midday trading in New York on Monday. All major averages edged higher. Tesla Inc. (TSLA) grabbed the market spotlight by securing a partnership with Baidu in China. Bank of Japan sent shockwaves through the forex market by intervening to support the value of the yen.
Benzinga · 04/29 18:14
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Clever Leaves Holdings Inc. Shares dipped 60% to $1.6498 on Monday. The company announced it will voluntarily delist its common shares from the Nasdaq. Shares of Deciphera Pharmaceuticals, Inc. Climbed 73% in today's mid-day session.
Benzinga · 04/29 17:04
12 Health Care Stocks Moving In Monday's Intraday Session
Deciphera Pharmaceuticals (NASDAQ:DCPH) stock moved upwards by 72.2% to $25.22 during Monday's regular session. The company's Q1 earnings report came out today. Deciphera shares rose to $2.0 billion. SINTX Techs and Koninklijke Philips also moved upwards.
Benzinga · 04/29 16:31
More
Webull provides a variety of real-time SLNO stock news. You can receive the latest news about Soleno Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About SLNO
Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate, Diazoxide Choline Extended-Release tablets (DCCR), extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), recently completed its Phase 3 development program. DCCR is a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. DCCR’s mode of action with targets in the brain, pancreas and fat tissue has the potential to impact complex diseases like PWS to reduce appetite, reduce food seeking, improve satiety, improve insulin and leptin resistance and reduce body fat. The Company has a Fast-Track designation for DCCR in PWS and an orphan designation for the drug in the United States and the European Union.